Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$63.29 USD
-2.96 (-4.47%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $65.18 +1.89 (2.99%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
Monopar Therapeutics Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
MNPR 63.29 -2.96(-4.47%)
Will MNPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength
Other News for MNPR
MNPR forms Boomer Buy Setup on September 20
Jack-in-the-box Bullish appears for MNPR after 0.59% move
MNPR makes New 52 Week Closing High on September 18
New 52 Week Closing High appears for MNPR after 4.61% move
Raymond James Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)